Please use this identifier to cite or link to this item:
Title: Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Authors: Comi, Giancarlo;Alroughani, Raed;Boster, Aaron L;Bass, Ann D;Berkovich, Regina;Fernández, Óscar;Kim, Ho Jin;Limmroth, Volker;Lycke, Jan;Macdonell, Richard A L;Sharrack, Basil;Singer, Barry A;Vermersch, Patrick;Wiendl, Heinz;Ziemssen, Tjalf;Jacobs, Alan;Daizadeh, Nadia;Rodriguez, Claudio E;Traboulsee, Anthony
Affiliation: Division of Neurology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada
The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO, USA
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Univ. Lille, INSERM U995, CHU Lille, FHU Imminent, F-59000 Lille, France
Department of Neurology, University of Münster, Münster, Germany
Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany
Sanofi, Cambridge, MA, USA
Department of Neurology, University Vita-Salute San Raffaele, Milan, Italy
Department of Medicine, Amiri Hospital, Sharq, Kuwait
OhioHealth Neurological Physicians, Columbus, OH, USA
Neurology Center of San Antonio, San Antonio, TX, USA
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA/Regina Berkovich, MD, PhD, Inc., West Hollywood, CA, USA
Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain
Research Institute and Hospital, National Cancer Center, Goyang, South Korea
Klinik für Neurologie und Palliativmedizin, Cologne, Germany
Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals, University of Sheffield, Sheffield, UK
Issue Date: 25-Nov-2019
EDate: 2019-11-25
Citation: Multiple sclerosis (Houndmills, Basingstoke, England) 2019; online first: 25 November
Abstract: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); <12-month follow-up after last alemtuzumab course. In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.
DOI: 10.1177/1352458519888610
ORCID: 0000-0001-5436-5804
PubMed URL: 31762387
Type: Journal Article
Subjects: Alemtuzumab
multiple sclerosis
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.